Limited central side effects of a β-subunit subtype-selective GABAA receptor allosteric modulator

Ryan F. Yoshimura, Minhtam B. Tran, Derk J. Hogenkamp, Timothy B. Johnstone, Jennifer Y. Xie, Frank Porreca, Kelvin W. Gee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

GABAergic anxiolytics have well-documented centrally mediated side effects including sedation, potentiation of ethanol, tolerance, abuse liability and memory impairment. Most research directed towards identifying an anxioselective GABAergic therapeutic has been based upon the theory that these side effects could be mitigated by avoiding α1/5-subunit GABAA receptors while specifically targeting those with the α2/3-subunit. Unfortunately, there are prominent exceptions to this theory and it has yet to be translated into clinical success. We previously demonstrated that β2/3-subunit- selective GABAA receptor-positive allosteric modulators act as anxiolytics with reduced sedation and ethanol potentiation regardless of their activity at α1-subunit GABAA receptors. The prototypical β2/3-subunit-selective positive allosteric modulator, 2-261, is further characterized here for additional side effects commonly associated with central GABAA receptor activation. In mice, 10 times the anxiolytic dose (10 mg/kg) of 2-261 does not induce behavioral tolerance in the elevated plus maze following a 2 week subchronic treatment. In rats, an anxiolytic dose (10 mg/kg) of 2-261 is inactive in conditioned place preference, suggesting a reduced abuse liability. In rats, 10 times the anxiolytic dose (100 mg/kg) of 2-261 does not have a significant amnestic effect in the radial arm maze, suggesting a greater therapeutic index for memory impairment. These results suggest that β2/3-subunit subtype-selective GABAA receptor-positive allosteric modulators not only have reduced sedative liability, but also a reduction in other central side effects commonly associated with broader GABAA receptor activation. β2/3-subunit-selective compounds may represent a novel design template for anxiolytics with benzodiazepine-like efficacy and mitigated side effects.

Original languageEnglish (US)
Pages (from-to)472-478
Number of pages7
JournalJournal of Psychopharmacology
Volume28
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Anti-Anxiety Agents
GABA-A Receptors
Ethanol
Hypnotics and Sedatives
Benzodiazepines
Therapeutics
Research

Keywords

  • allosteric
  • Anxiolytics
  • benzodiazepine
  • GABAergic

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Medicine(all)

Cite this

Yoshimura, R. F., Tran, M. B., Hogenkamp, D. J., Johnstone, T. B., Xie, J. Y., Porreca, F., & Gee, K. W. (2014). Limited central side effects of a β-subunit subtype-selective GABAA receptor allosteric modulator. Journal of Psychopharmacology, 28(5), 472-478. https://doi.org/10.1177/0269881113507643

Limited central side effects of a β-subunit subtype-selective GABAA receptor allosteric modulator. / Yoshimura, Ryan F.; Tran, Minhtam B.; Hogenkamp, Derk J.; Johnstone, Timothy B.; Xie, Jennifer Y.; Porreca, Frank; Gee, Kelvin W.

In: Journal of Psychopharmacology, Vol. 28, No. 5, 2014, p. 472-478.

Research output: Contribution to journalArticle

Yoshimura, Ryan F. ; Tran, Minhtam B. ; Hogenkamp, Derk J. ; Johnstone, Timothy B. ; Xie, Jennifer Y. ; Porreca, Frank ; Gee, Kelvin W. / Limited central side effects of a β-subunit subtype-selective GABAA receptor allosteric modulator. In: Journal of Psychopharmacology. 2014 ; Vol. 28, No. 5. pp. 472-478.
@article{659eac8509a74823a21f5842d1b1a995,
title = "Limited central side effects of a β-subunit subtype-selective GABAA receptor allosteric modulator",
abstract = "GABAergic anxiolytics have well-documented centrally mediated side effects including sedation, potentiation of ethanol, tolerance, abuse liability and memory impairment. Most research directed towards identifying an anxioselective GABAergic therapeutic has been based upon the theory that these side effects could be mitigated by avoiding α1/5-subunit GABAA receptors while specifically targeting those with the α2/3-subunit. Unfortunately, there are prominent exceptions to this theory and it has yet to be translated into clinical success. We previously demonstrated that β2/3-subunit- selective GABAA receptor-positive allosteric modulators act as anxiolytics with reduced sedation and ethanol potentiation regardless of their activity at α1-subunit GABAA receptors. The prototypical β2/3-subunit-selective positive allosteric modulator, 2-261, is further characterized here for additional side effects commonly associated with central GABAA receptor activation. In mice, 10 times the anxiolytic dose (10 mg/kg) of 2-261 does not induce behavioral tolerance in the elevated plus maze following a 2 week subchronic treatment. In rats, an anxiolytic dose (10 mg/kg) of 2-261 is inactive in conditioned place preference, suggesting a reduced abuse liability. In rats, 10 times the anxiolytic dose (100 mg/kg) of 2-261 does not have a significant amnestic effect in the radial arm maze, suggesting a greater therapeutic index for memory impairment. These results suggest that β2/3-subunit subtype-selective GABAA receptor-positive allosteric modulators not only have reduced sedative liability, but also a reduction in other central side effects commonly associated with broader GABAA receptor activation. β2/3-subunit-selective compounds may represent a novel design template for anxiolytics with benzodiazepine-like efficacy and mitigated side effects.",
keywords = "allosteric, Anxiolytics, benzodiazepine, GABAergic",
author = "Yoshimura, {Ryan F.} and Tran, {Minhtam B.} and Hogenkamp, {Derk J.} and Johnstone, {Timothy B.} and Xie, {Jennifer Y.} and Frank Porreca and Gee, {Kelvin W.}",
year = "2014",
doi = "10.1177/0269881113507643",
language = "English (US)",
volume = "28",
pages = "472--478",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Limited central side effects of a β-subunit subtype-selective GABAA receptor allosteric modulator

AU - Yoshimura, Ryan F.

AU - Tran, Minhtam B.

AU - Hogenkamp, Derk J.

AU - Johnstone, Timothy B.

AU - Xie, Jennifer Y.

AU - Porreca, Frank

AU - Gee, Kelvin W.

PY - 2014

Y1 - 2014

N2 - GABAergic anxiolytics have well-documented centrally mediated side effects including sedation, potentiation of ethanol, tolerance, abuse liability and memory impairment. Most research directed towards identifying an anxioselective GABAergic therapeutic has been based upon the theory that these side effects could be mitigated by avoiding α1/5-subunit GABAA receptors while specifically targeting those with the α2/3-subunit. Unfortunately, there are prominent exceptions to this theory and it has yet to be translated into clinical success. We previously demonstrated that β2/3-subunit- selective GABAA receptor-positive allosteric modulators act as anxiolytics with reduced sedation and ethanol potentiation regardless of their activity at α1-subunit GABAA receptors. The prototypical β2/3-subunit-selective positive allosteric modulator, 2-261, is further characterized here for additional side effects commonly associated with central GABAA receptor activation. In mice, 10 times the anxiolytic dose (10 mg/kg) of 2-261 does not induce behavioral tolerance in the elevated plus maze following a 2 week subchronic treatment. In rats, an anxiolytic dose (10 mg/kg) of 2-261 is inactive in conditioned place preference, suggesting a reduced abuse liability. In rats, 10 times the anxiolytic dose (100 mg/kg) of 2-261 does not have a significant amnestic effect in the radial arm maze, suggesting a greater therapeutic index for memory impairment. These results suggest that β2/3-subunit subtype-selective GABAA receptor-positive allosteric modulators not only have reduced sedative liability, but also a reduction in other central side effects commonly associated with broader GABAA receptor activation. β2/3-subunit-selective compounds may represent a novel design template for anxiolytics with benzodiazepine-like efficacy and mitigated side effects.

AB - GABAergic anxiolytics have well-documented centrally mediated side effects including sedation, potentiation of ethanol, tolerance, abuse liability and memory impairment. Most research directed towards identifying an anxioselective GABAergic therapeutic has been based upon the theory that these side effects could be mitigated by avoiding α1/5-subunit GABAA receptors while specifically targeting those with the α2/3-subunit. Unfortunately, there are prominent exceptions to this theory and it has yet to be translated into clinical success. We previously demonstrated that β2/3-subunit- selective GABAA receptor-positive allosteric modulators act as anxiolytics with reduced sedation and ethanol potentiation regardless of their activity at α1-subunit GABAA receptors. The prototypical β2/3-subunit-selective positive allosteric modulator, 2-261, is further characterized here for additional side effects commonly associated with central GABAA receptor activation. In mice, 10 times the anxiolytic dose (10 mg/kg) of 2-261 does not induce behavioral tolerance in the elevated plus maze following a 2 week subchronic treatment. In rats, an anxiolytic dose (10 mg/kg) of 2-261 is inactive in conditioned place preference, suggesting a reduced abuse liability. In rats, 10 times the anxiolytic dose (100 mg/kg) of 2-261 does not have a significant amnestic effect in the radial arm maze, suggesting a greater therapeutic index for memory impairment. These results suggest that β2/3-subunit subtype-selective GABAA receptor-positive allosteric modulators not only have reduced sedative liability, but also a reduction in other central side effects commonly associated with broader GABAA receptor activation. β2/3-subunit-selective compounds may represent a novel design template for anxiolytics with benzodiazepine-like efficacy and mitigated side effects.

KW - allosteric

KW - Anxiolytics

KW - benzodiazepine

KW - GABAergic

UR - http://www.scopus.com/inward/record.url?scp=84899820018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899820018&partnerID=8YFLogxK

U2 - 10.1177/0269881113507643

DO - 10.1177/0269881113507643

M3 - Article

C2 - 24108410

AN - SCOPUS:84899820018

VL - 28

SP - 472

EP - 478

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 5

ER -